| Eligibility |
Inclusion Criteria:
- Agreement to comply with safety guidelines to minimize the risk of contamination to
COVID-19;
- Agreement to perform a molecular test for the detection of COVID-19 to enter the
study;
- Healthy participants;
- Non-injured skin in the test region;
- Agreement to adhere to the test procedures and requirements and to attend the
institute on the day(s) and at the time(s) determined for the evaluations;
- Ability to consent to participation in the study;
- Age from 18 to 70 years;
- Phototype (Fitzpatrick): II and III;
- Any gender
Exclusion Criteria:
- Participants who belong to the risk group for COVID-19, that is, with diabetes, with
chronic cardiovascular, renal and respiratory problems, immunosuppressed or other
conditions that the physician deems as belonging to the risk group;
- Skin marks in the experimental area;
- Active dermatoses (local or widespread);
- Pregnant or breastfeeding women;
- History of allergic reactions, irritation or intense feelings of discomfort to topical
products;
- History of phototoxic or photoallergic reactions;
- History of allergy to materials used in the study;
- History of atopy;
- Personal or family pathological history of skin cancer;
- History of pathologies aggravated or triggered by ultraviolet radiation;
- Carriers of immunodeficiencies;
- Intense sun exposure or tanning session up to 15 days before the initial evaluation;
- Predicted intense sun exposure or tanning session during the course of the study;
- Predicted bathing in the sea, pool or bathtub during the study;
- Participants who practice water sports;
- Dermography;
- Use of the following topical or systemic drugs: immunosuppressants, antihistamines,
non-hormonal anti-inflammatory drugs and corticoids up to 2 weeks prior to selection
or, considering deposit corticoids, the interval shall be 1 month prior to selection;
- Use of topical or systemic photosensitizing drugs;
- Treatment with acid vitamin A and/or its derivatives via oral or topical until 1 month
before the beginning of the study;
- Aesthetic and/or body dermatological treatment until 3 weeks before selection;
- Vaccination during the study or until 3 weeks before the study;
- Being or having participated in another clinical trial terminated less than 7 days
before selection, in case the previous trial is acceptable in use;
- Being or having participated in another clinical trial terminated less than 21 days
ago, in case the previous trial is compatible or Adverse Reaction investigative;
- History of absence of adherence or unwillingness to adhere to the study protocol;
- Professionals directly involved in the execution of this protocol and their relatives.
- Participants who have COVID-19, or who present symptoms indicative of the disease in
the last 14 days.
- Any condition not mentioned above that, in the opinion of the investigator, may
compromise the evaluation of the study.
|
